hfpef semaglutide in across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial Wegovy analysis could boost Novo

For patients and clinicians, the practical takeaway is that retatrutide's side effect profile is broadly similar to existing peptide-based obesity treatments, with the addition of dysesthesia as a novel but generally manageable consideration

Factors that may influence maintenance include nutrition habits, physical activity, sleep quality, stress management and long-term consistency

Semaglutide is one of several GLP-1 agonists approved for weight loss others are liraglutide (Saxenda) and tirzepatide (Zepbound)

While compounded medications are not FDA-approved, they use the same active pharmaceutical ingredients as brand-name products studied in clinical trials

Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase